Association of 87851G> A, LMTK2 nucleotide transition with benign prostatic hyperplasia: a case-control study in Mazandaran population

Recently, biomarkers have been used for diagnosis and prevention of several types of malignant or benign tumors such as the prostate. One of these markers is the LMTK2that codes a transmembrane serine/tyrosine kinase which plays role in membrane transferring. LMTK2 has been identified to regulate prostate-specific antigen (PSA) and vascular endothelial growth factor (VEGF) which are related to tumorigenesis. Also, downregulation of LMTK2 might contribute to prostate cancer formation. To investigate the correlation of rs7791463 which is located on intron 9 of LMTK2 and benign prostatic hyperplasia (BPH), the Boiling DNA extraction and the PCR-RFLP methods have been used for the blood sample of 70 patients and 70 normal controls participants. The PCRproduct has been 257 bp which has been cut by NcoI restriction enzyme in the G allele. The frequencies of genotypes that obtained in the controls were 22.8% GG, 51.4% AG and 25.7% AA, and in the cases were 12.8% GG, 61.42% AG and 25.7% AA. Also, theallelicfrequencies that calculated in controls were 51.4 and 48.5 percent for A and G allele, and in cases were 56.4 and 43.5 percent for A and G allele. Statistical analysis revealed that the distribution of genotypes for 87851G> Atransition does not show Significant different (P= 0.36, OR=1.26; 95% CI: 0.76-2.1) in case and control groups. In conclusion, the present study suggests that 87851G> A transition is not associated with BPH.

Keywords:

LMTK2 , Benign Prostatic Hyperplasia , Polymorphism